GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (ATH:LAVI) » Definitions » YoY EBITDA Growth

Lavipharm (ATH:LAVI) YoY EBITDA Growth : -8.11% (As of Jun. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Lavipharm YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Lavipharm's YoY EBITDA Growth for the quarter that ended in Jun. 2024 was -8.11%.

Lavipharm's EBITDA per Share for the six months ended in Jun. 2024 was €0.03.

Lavipharm YoY EBITDA Growth Historical Data

The historical data trend for Lavipharm's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lavipharm YoY EBITDA Growth Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial -8.28 24.41 -1.61 -28.96 -77.31

Lavipharm Semi-Annual Data
Dec17 Dec18 Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -22.30 8.45 -82.30 -71.43 -8.11

Lavipharm YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Lavipharm's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(0.059-0.26)/ | 0.26 |
=-77.31 %

Lavipharm's YoY EBITDA Growth for the quarter that ended in Jun. 2024 is calculated as:

YoY EBITDA Growth (Q: Jun. 2024 )
=(EBITDA per Share (Q: Jun. 2024 )-EBITDA per Share (Q: Jun. 2023 )) / | EBITDA per Share (Q: Jun. 2023 )) |
=(0.034-0.037)/ | 0.037 |
=-8.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lavipharm YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Lavipharm's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Lavipharm Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lavipharm SA (ATH:LAVI) » Definitions » YoY EBITDA Growth
Comparable Companies
ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA SHSE:688506 BOM:500087 SZSE:000538 TSE:4507 UTHR NSE:TORNTPHARM BOM:500124 NBIX BOM:543904 BOM:532321
Traded in Other Exchanges
BXA0:Germany
Address
Agias Marinas Street, PO Box 59, Peania Attica, GRC, 19002
Website
http://www.lavipharm.com
Lavipharm SA develops, manufactures, markets and distributes pharmaceutical, cosmetic and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumer' needs for health and wellbeing. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, General Medicine, Self- Treatment and Dermocosmetic care.

Lavipharm Headlines

No Headlines